Monopar Therapeutics (MNPR) CMO uses plan to exercise options
Rhea-AI Filing Summary
Monopar Therapeutics (MNPR) reported that Acting Chief Medical Officer Patrice Rioux exercised 1,380 Stock Options for Common Stock on 2026-08-26 at an exercise price of $0.005 per share, converting them into 1,380 Common Shares. On the same date, 1 Common Share was sold at $111.26 per share. The option exercise exhausted this particular option grant, leaving 0 derivative shares reported as remaining from it. These transactions were effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
3 txns
Insider
RIOUX PATRICE
Role
Insider
Sold
1 shs ($111.26)
Approx. gross sale proceeds
$111.26
Approx. exercise cost
$6.90
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F1, F2 | 1,380 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 1,380 | $0.005 | $6.90 |
| Sale | Common Stock F1 | 1 | $111.26 | $111.26 |
Holdings After Transaction:
Stock Option — 0 shares (Direct);
Common Stock — 5,065 shares (Direct)
Footnotes (2)
- F1. This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.
- F2. On December 15, 2016, the reporting person was granted stock options to purchase up to 1,400 shares of common stock vested: 238 shares on January 15, 2017; 224 shares on February 15, 2017; 238 shares on March 15, 2017; 224 shares on April 15, 2017; 238 shares on May 15, 2017; and 238 shares on June 15, 2017.
Key Figures
Options exercised: 1,380 shares of Common Stock
Option exercise price: $0.005 per share
Common shares sold: 1 share
+3 more
6 metrics
Options exercised
1,380 shares of Common Stock
Stock Options exercised on 2026-08-26
Option exercise price
$0.005 per share
Exercise price for 1,380 Stock Options on 2026-08-26
Common shares sold
1 share
Sale of Common Stock on 2026-08-26
Sale price
$111.26 per share
Price for 1 Common Share sold on 2026-08-26
Options from original grant
1,400 shares
Stock options granted on 2016-12-15
Derivative shares remaining after exercise
0 shares
Total shares following transaction for this Stock Option position
Key Terms
Rule 10b5-1 Plan, Stock Option, derivative security, transaction code S
4 terms
Rule 10b5-1 Plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 Plan executed"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
Stock Option financial
"On December 15, 2016, the reporting person was granted stock options"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
transaction code S regulatory
"transaction_code_description": "Sale in open market or private transaction"
FAQ
What insider transactions did MNPR’s Acting Chief Medical Officer report on 2026-08-26?
The Acting Chief Medical Officer, Patrice Rioux, exercised 1,380 Stock Options into Common Stock at $0.005 per share and sold 1 Common Share at $111.26 per share on 2026-08-26.
Were the MNPR insider transactions made under a Rule 10b5-1 trading plan?
Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026, and the Rule 10b5-1 checkbox is marked as affirmed.
What options did the MNPR insider exercise in this Form 4?
Patrice Rioux exercised 1,380 Stock Options for Monopar Therapeutics Common Stock at an exercise price of $0.005 per share on 2026-08-26, resulting in the acquisition of 1,380 Common Shares and leaving 0 shares reported remaining from this option grant.
What was the sale reported in the MNPR Form 4 filing?
The filing reports a sale of 1 share of Monopar Therapeutics Common Stock on 2026-08-26 at a price of $111.26 per share, classified as a sale in open market or private transaction under transaction code S.
What was the original size of the MNPR stock option grant referenced in this Form 4?
A footnote states that on December 15, 2016, the reporting person was granted stock options to purchase up to 1,400 shares of Monopar Therapeutics common stock, which vested in several installments between January 15, 2017 and June 15, 2017.
AI-generated analysis. How Rhea-AI works. Not financial advice.
